Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis
Authors
Keywords
-
Journal
EUROPEAN UROLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-08-19
DOI
10.1016/j.eururo.2022.08.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
- (2022) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
- (2022) Karim Fizazi et al. LANCET
- Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: Meta-analysis of individual participant data from randomized trials.
- (2022) Claire Louise Vale et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer
- (2021) Lin Wang et al. JAMA Oncology
- A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
- (2021) Winnie W. Y. Sung et al. Frontiers in Oncology
- Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer
- (2021) Rémi Pelloux-Prayer et al. Clinical Genitourinary Cancer
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
- (2021) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
- (2021) A.J. Armstrong et al. ANNALS OF ONCOLOGY
- LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
- (2021) K. Fizazi et al. ANNALS OF ONCOLOGY
- Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis
- (2021) Keiichiro Mori et al. BJU INTERNATIONAL
- Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
- (2021) Arun A. Azad et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
- (2021) Hannah L. Rush et al. JOURNAL OF CLINICAL ONCOLOGY
- Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial
- (2020) Alberto Martini et al. PROSTATE CANCER AND PROSTATIC DISEASES
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
- (2020) Philip Cornford et al. EUROPEAN UROLOGY
- Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review
- (2020) Yuhan Wang et al. Frontiers in Oncology
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.
- (2019) Christopher Sweeney et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
- (2019) Alex P. Hoyle et al. EUROPEAN UROLOGY
- Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
- (2019) N W Clarke et al. ANNALS OF ONCOLOGY
- Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis
- (2019) Niranjan J. Sathianathen et al. EUROPEAN UROLOGY
- Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
- (2018) M R Sydes et al. ANNALS OF ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for Reporting of Statistics for Clinical Research in Urology
- (2018) Melissa Assel et al. EUROPEAN UROLOGY
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
- (2016) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
- (2012) M. Thadani-Mulero et al. CANCER RESEARCH
- Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer
- (2011) Peter S. Nelson JOURNAL OF CLINICAL ONCOLOGY
- Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial
- (2010) Beth S Woods et al. BMC Medical Research Methodology
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now